Seres Therapeutics Inc (NASDAQ:MCRB) – FBR & Co lifted their Q1 2017 earnings per share (EPS) estimates for shares of Seres Therapeutics in a report issued on Monday, Zacks Investment Research reports. FBR & Co analyst V. Bernardino now expects that the biotechnology company will post earnings per share of ($0.53) for the quarter, up from their previous estimate of ($0.56). FBR & Co has a “Outperform” rating and a $18.00 price objective on the stock. FBR & Co also issued estimates for Seres Therapeutics’ Q2 2017 earnings at ($0.61) EPS, Q3 2017 earnings at ($0.66) EPS, Q4 2017 earnings at ($0.68) EPS, FY2017 earnings at ($2.48) EPS, FY2018 earnings at ($2.44) EPS, FY2019 earnings at ($2.39) EPS, FY2020 earnings at $0.86 EPS and FY2021 earnings at $3.72 EPS.
MCRB has been the subject of several other reports. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 2nd. Cantor Fitzgerald set a $16.00 target price on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 31st. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a research note on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $23.20.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 1.97% on Thursday, hitting $9.45. 120,565 shares of the company’s stock were exchanged. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $35.98. The stock’s market cap is $381.48 million. The company’s 50-day moving average price is $10.48 and its 200 day moving average price is $10.53.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, March 16th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.07. The firm earned $3 million during the quarter, compared to analyst estimates of $3 million. The company’s quarterly revenue was up NaN% compared to the same quarter last year.
Several hedge funds have recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in shares of Seres Therapeutics during the first quarter worth $136,000. Bank of Montreal Can boosted its stake in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,829 shares during the period. Teachers Advisors LLC raised its position in shares of Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock valued at $407,000 after buying an additional 12,462 shares during the last quarter. Artal Group S.A. raised its position in shares of Seres Therapeutics by 40.0% in the fourth quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock valued at $6,930,000 after buying an additional 200,000 shares during the last quarter. Finally, Ellington Management Group LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter valued at $107,000. 77.62% of the stock is currently owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with our FREE daily email newsletter.